<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> (FA) is characterized by progressive marrow failure, congenital anomalies, and predisposition to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Biallelic FANCD1/BRCA2 mutations are the genetic basis of disease in a small proportion of children with FA with earlier <z:hpo ids='HP_0003674'>onset</z:hpo> and increased incidence of <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with FA have increased sensitivity to chemotherapy and radiation, and upon development of a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e>, require modification of these therapies </plain></SENT>
<SENT sid="3" pm="."><plain>We report clinical and molecular features of three patients with FA associated with FANCD1/BRCA2 mutations, including two novel mutations, and discuss treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and associated side effects in this particularly vulnerable group </plain></SENT>
</text></document>